Prime Medicine, Inc.

Prime Medicine, Inc. is a biotechnology company dedicated to developing a new class of genetic medicines using its proprietary 'Prime Editing' platform. The company's mission is to provide durable and potentially curative treatment options for patients suffering from diseases caused by genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Headquartered in Cambridge, Massachusetts, Prime Medicine was founded in 2019 and aims to address a wide spectrum of diseases through its innovative gene-editing technology.

The core of Prime Medicine's approach is its Prime Editing technology, which functions as a 'DNA word processor' to precisely 'search and replace' disease-causing genetic sequences without introducing double-strand DNA breaks. This technology is believed to have the potential to correct approximately 90% of known disease-causing mutations across various organisms, organs, and cell types. The company is advancing a diversified portfolio of investigational therapeutic programs focused on hematology, immunology & oncology, liver, and lung indications. Key pipeline candidates include PM359 for Chronic Granulomatous Disease (CGD), PM577 for Wilson Disease, and PM647 for Alpha-1 Antitrypsin Deficiency (AATD).

Recent notable developments include the U.S. FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for PM359 for CGD in June 2026, based on promising Phase 1/2 clinical data demonstrating durable immune function restoration. In the same month, New Zealand granted clinical trial authorization for PM577a for Wilson Disease, marking Prime Medicine's first clinical authorization for an in vivo Prime Editing therapy. Allan Reine, M.D., serves as the Chief Executive Officer, having been appointed in May 2025. As a publicly traded company on NASDAQ under the ticker PRME, Prime Medicine operates as a pre-commercial platform biotech, with its value driven by the advancement of its pipeline candidates and strategic collaborations, including partnerships with Bristol Myers Squibb and the Cystic Fibrosis Foundation.